cytokine monitoring
Compare CAR‑T vs Chronic Disease Management: Which Wins?
In the CASTLE trial, 60 patients received CAR-T, and the early data suggest CAR-T can outperform standard chronic disease management for refractory autoimmune conditions, though long-term cost and infrastructure remain important considerations. Medical Disclaimer: This article is for informational purposes only and does not constitute medical advice. Always consult a